Home / News / Research & Clinical Trials

Researchers: Modified Smallpox Virus Could Offer Hope to Mesothelioma Patients

Research & Clinical Trials

Written by Faith Franz

Fact Checked

Cite This Article

Reading Time: 2 mins

Publication Date: 09/07/2011

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

Assisting mesothelioma patients and their loved ones since 2006.
Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
A+ rating from the Better Business Bureau.
5-star reviewed mesothelioma and support organization.

Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."

Lashawn

Mesothelioma patient’s daughter

Read Our Testimonials

Canadian researchers are testing a new version of a small pox virus with the hope that it will help doctors deliver medicine to hard-to-treat cancerous tumors, including those typically associated with malignant mesothelioma.

A study published in the September 2011 issue of Nature explored the genetic engineering of a poxvirus known as JX-594. The drug was designed by Jennerex, Inc. to selectively infect cancerous tissue and produce proteins that tell the body to destroy the tumor.

The trial showed that the virus had no effect on healthy cells, but 87 percent of patients who received the highest dose of the virus showed that the virus had spread throughout the patients’ tumors. Ten weeks after receiving an injection of the virus, 13 of 23 patients had experienced halted growth or reduction of their tumors.

One of the most prevalent ways to deliver drugs directly to metastatic solid tumors is targeted therapy. Targeted therapy is expected to increase the efficacy and safety of cancer therapy while making cancer cells more receptive to treatment.

The JX-594 virus is different from other viruses used in earlier types of targeted therapy because it can be administered to the bloodstream. Most other genetically altered viruses need to be placed directly into the tumor in order to be effective, but the original small pox virus is blood-borne. The JX-594 virus is found to have mild side effects, many of which are no more severe than flu-like symptoms lasting approximately one day.

The virus is scheduled to be the focus of a phase IIb trial at the Ottawa Hospital Research Institute. Although the trial will examine its effects on primary liver cancer patients, researchers hope that the findings of the study can be used to help develop treatments for all forms of cancer.

Other types of gene therapy studies are being conducted to develop novel therapies for mesothelioma patients.